These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26911153)

  • 1. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).
    Lamichhane D; Weinstein A
    Lupus; 2016 Aug; 25(9):1050-3. PubMed ID: 26911153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
    Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
    Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
    Hui-Yuen JS; Gartshteyn Y; Ma M; O'Malley T; Conklin J; Eichenfield AH; Imundo LF; Dervieux T; Askanase AD
    Lupus; 2018 Dec; 27(14):2262-2268. PubMed ID: 30376789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers.
    Calano SJ; Shih PA; Liu CC; Kao AH; Navratil JS; Manzi S; Ahearn JM
    Adv Exp Med Biol; 2006; 586():381-90. PubMed ID: 16893085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-bound complement activation products associate with lupus severity in SLE.
    Arriens C; Alexander RV; Narain S; Saxena A; Collins CE; Wallace DJ; Massarotti E; Conklin J; Kalunian KC; Putterman C; Ramsey-Goldman R; Buyon JP; Askanase A; Furie RA; James JA; Bello GA; Manzi S; Ahearn J; O'Malley T; Weinstein A; Dervieux T
    Lupus Sci Med; 2020 Apr; 7(1):. PubMed ID: 32371480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification.
    Ahearn JM; Liu CC; Manzi S
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1133-1142. PubMed ID: 29025354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Complement Activation in SLE.
    Weinstein A; Alexander RV; Zack DJ
    Curr Rheumatol Rep; 2021 Feb; 23(3):16. PubMed ID: 33569681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New advances in measurement of complement activation: lessons of systemic lupus erythematosus.
    Liu CC; Manzi S; Danchenko N; Ahearn JM
    Curr Rheumatol Rep; 2004 Oct; 6(5):375-81. PubMed ID: 15355750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
    Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
    Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenesis of systemic lupus erythematosus (SLE)--the central role of complement].
    Trendelenburg M
    Ther Umsch; 2005 May; 62(5):285-91. PubMed ID: 15945218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus.
    Rubin RL; Teodorescu M; Beutner EH; Plunkett RW
    Lupus; 2004; 13(4):249-56. PubMed ID: 15176661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACR classification criteria for systemic lupus erythematosus: complement components.
    Nived O; Sturfelt G
    Lupus; 2004; 13(11):877-9. PubMed ID: 15580986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy.
    Abramson SB; Buyon JP
    Am J Reprod Immunol; 1992; 28(3-4):183-7. PubMed ID: 1285875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.
    Cines DB; Lyss AP; Reeber M; Bina M; DeHoratius RJ
    J Clin Invest; 1984 Mar; 73(3):611-25. PubMed ID: 6368583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways.
    Ceribelli A; Andreoli L; Cavazzana I; Franceschini F; Radice A; Rimoldi L; Sinico RA; Carlsson M; Wieslander J; Tincani A
    Ann N Y Acad Sci; 2009 Sep; 1173():427-34. PubMed ID: 19758182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
    Li J; An L; Zhang Z
    Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement and its breakdown products in SLE.
    Sturfelt G; Truedsson L
    Rheumatology (Oxford); 2005 Oct; 44(10):1227-32. PubMed ID: 15972354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-bound complement activation products in SLE.
    Ramsey-Goldman R; Li J; Dervieux T; Alexander RV
    Lupus Sci Med; 2017; 4(1):e000236. PubMed ID: 29214038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complement system in systemic lupus erythematosus: an update.
    Leffler J; Bengtsson AA; Blom AM
    Ann Rheum Dis; 2014 Sep; 73(9):1601-6. PubMed ID: 24845390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
    Ramsey-Goldman R; Alexander RV; Conklin J; Arriens C; Narain S; Massarotti EM; Wallace DJ; Collins CE; Saxena A; Putterman C; Brady K; Kalunian KC; Weinstein A
    ACR Open Rheumatol; 2021 Feb; 3(2):116-123. PubMed ID: 33538130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.